Trial Profile
To characterize the glycometabolism and the distribution and extent of amyloid-β (Aβ) protein in patients with Alzheimer's disease, and to establish a diagnosis modality of AD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2018
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary) ; Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 04 Oct 2018 New trial record